{"title":"Pembrolizumab + EP not cost effective vs EP as first-line treatment for SCLC in the USA","authors":"","doi":"10.1007/s40274-021-08248-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"178 1","pages":"17 - 17"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics & Outcomes News","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40274-021-08248-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
